Elevation Oncology Balance Sheet Health
Financial Health criteria checks 5/6
Elevation Oncology has a total shareholder equity of $69.4M and total debt of $31.0M, which brings its debt-to-equity ratio to 44.7%. Its total assets and total liabilities are $106.3M and $36.9M respectively.
Key information
44.7%
Debt to equity ratio
US$31.02m
Debt
| Interest coverage ratio | n/a |
| Cash | US$103.07m |
| Equity | US$69.36m |
| Total liabilities | US$36.95m |
| Total assets | US$106.30m |
Recent financial health updates
We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10
We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25Recent updates
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
May 03Elevation Oncology: Rising On News, But Not The Time To Buy
Jan 17Elevation Oncology GAAP EPS of -$0.86 misses by $0.07
Aug 04Elevation Oncology secured $50M loan facility with K2 HealthVentures
Jul 28We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25Financial Position Analysis
Short Term Liabilities: ELEV's short term assets ($105.3M) exceed its short term liabilities ($5.9M).
Long Term Liabilities: ELEV's short term assets ($105.3M) exceed its long term liabilities ($31.0M).
Debt to Equity History and Analysis
Debt Level: ELEV has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ELEV's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELEV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ELEV has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 26.2% each year.